184
systematic reviews. Lancet 2011;378:571–583.
56.
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection.
Lancet Infect Dis 2005;5:558–567.
57.
van Heeswijk R, Vandevoorde A, Verboven P, Boogaerts G, De Paepe E, van
Solingen-Ristea R, et al. The pharmacokinetic interaction between methadone and
the investigational HCV protease inhibitor telaprevir. J Hepatol 2011;54:S491.
58.
Luo X, Trevejo J, Van Heeswijk R, Garg V. No significant effect of the HCV
protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of
buprenorphine in HCV-negative volunteers. Global Antivir J 2011;7:116–117.
59.
Deterding K, Gruner N, Buggisch P, Wiegand J, Galle PR, Spengler U, et al.
Delayed versus immediate treatment for patients with acute hepatitis C: a
randomised controlled non-inferiority trial. Lancet Infect Dis 2013;13:497–506.
60.
Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol
2008;103:1283–1297.
61.
Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J
Hepatol 2005;42:S108–S114.
62.
Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and
remaining challenges. J Hepatol 2008;49:625–633.
63.
Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment
of hepatitis C. Hepatology 2004;39:1147–1171.
64.
Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, et al. Long-
term follow-up after successful interferon therapy of acute hepatitis C. Hepatology
2004;40:98–107.
65.
European ATNAHCICP. Acute hepatitis C in HIV-infected individuals:
recommendations from the European AIDS Treatment Network (NEAT) consensus
conference. AIDS 2011;25:399–409.
66.
Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, et al.Acute
hepatitis C: a 24-week course of pegylated interferon alpha-2b versus a 12-week
course of pegylated interferon alpha-2b alone or with ribavirin. Hepatology
2014;59:2101–2109.
67.
Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, et al. Treatment
optimization and prediction of HCV clearance in patients with acute HCV infection.
J Hepatol 2013;59:221–228.
68.
Fierer DS, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, et
al.Telaprevir in the treatment of acute hepatitis C virus infection in HIVinfectedmen.
Clin Infect Dis 2014;58:873–879.
69.
Camma C, Almasio P, Craxi A. Interferon as treatment for acute hepatitis C.A meta-
analysis. Dig Dis Sci 1996;41:1248–1255.
70.
Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et
al. Acute hepatitis C: high rate of both spontaneous and treatmentinducedviral
clearance. Gastroenterology 2003;125:80–88.
71.
Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute
hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat
2006;13:34–41.
72.
Poynard T, Regimbeau C, Myers RP, Thevenot T, Leroy V, Mathurin P, et
al.Interferon for acute hepatitis C. Cochrane Database Syst Rev2002;1:CD000369.
73.
Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al.
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by
repeated measurements of serum viral load. Hepatology 2003;37:60–64.
